News & Updates

Show Multimedia Only

Empagliflozin 25 mg confers greater kidney protection than SGLT2i 10 mg in T2D

03 Nov 2025 by

In patients with type 2 diabetes (T2D), empagliflozin 25 mg daily offers greater kidney protection than its 10 mg daily dose or dapagliflozin 10 mg daily, a retrospective cohort study in Hong Kong has shown.

Empagliflozin 25 mg confers greater kidney protection than SGLT2i 10 mg in T2D

03 Nov 2025

Sultiame shows therapeutic potential in obstructive sleep apnoea

02 Nov 2025

In patients with obstructive sleep apnoea (OSA), treatment with sultiame yields improvements in nocturnal hypoxia, sleep quality, and excessive daytime sleepiness, according to a phase II trial.

Sultiame shows therapeutic potential in obstructive sleep apnoea

02 Nov 2025

Denifanstat reduces lesions in acne vulgaris

01 Nov 2025 by

The fatty acid synthase inhibitor denifanstat shows potential for treating moderate-to-severe acne vulgaris, with good safety and tolerability, as demonstrated in a study from China presented at EADV 2025.

Denifanstat reduces lesions in acne vulgaris

01 Nov 2025

Setmelanotide delivers long-term benefits in adults with obesity

31 Oct 2025

The melanocortin-4 receptor agonist setmelanotide has demonstrated long-term clinical benefit and an acceptable safety profile in adults with monogenic or syndromic obesity, reports a study.

Setmelanotide delivers long-term benefits in adults with obesity

31 Oct 2025

CTC-DMARD lowers risk of treatment failure in nonanterior sarcoidosis uveitis

31 Oct 2025 by

Treatment with corticosteroid (CTC) plus conventional disease-modifying antirheumatic drug (C-DMARD) demonstrates an acceptable safety profile and appears to be more efficient than CTC alone in patients with nonanterior sarcoidosis-related uveitis, reports a study.

CTC-DMARD lowers risk of treatment failure in nonanterior sarcoidosis uveitis

31 Oct 2025

Ketamine infusions no better than midazolam infusions for inpatient depression treatment

31 Oct 2025 by

Administering serial ketamine infusions does not show a clear advantage over serial midazolam infusions for reducing depressive symptoms in patients receiving standard inpatient psychiatric care, according to the KARMA-Dep 2 trial.

Ketamine infusions no better than midazolam infusions for inpatient depression treatment

31 Oct 2025

Original New Drug Application Approvals by US FDA (16-30 September 2025)

31 Oct 2025

New drug applications approved by US FDA as of 16-30 September 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 September 2025)

31 Oct 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-September-2025

31 Oct 2025

New drug applications approved by US FDA as of 1-15 September 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-September-2025

31 Oct 2025

Cagrilintide-semaglutide tied to weight loss in adults with obesity, T2D

30 Oct 2025 by

Combination treatment with cagrilintide and semaglutide significantly reduced body weight in patients with overweight or obesity and type 2 diabetes (T2D), according to the REDEFINE 2 trial presented at EASD 2025.

Cagrilintide-semaglutide tied to weight loss in adults with obesity, T2D

30 Oct 2025

Reducing pharmaceutical sodium content helps manage BP elevations in narcolepsy

29 Oct 2025

In patients with narcolepsy, switching from high- to low-sodium oxybate results in substantial reductions in daily medication-related sodium intake and, in turn, blood pressure levels (BP), according to a study.

Reducing pharmaceutical sodium content helps manage BP elevations in narcolepsy

29 Oct 2025

News & Updates

Filter by Specialty:

Specialty:

Empagliflozin 25 mg confers greater kidney protection than SGLT2i 10 mg in T2D

Empagliflozin 25 mg confers greater kidney protection than SGLT2i 10 mg in T2D

Sultiame shows therapeutic potential in obstructive sleep apnoea

Sultiame shows therapeutic potential in obstructive sleep apnoea

Denifanstat reduces lesions in acne vulgaris

Denifanstat reduces lesions in acne vulgaris

Setmelanotide delivers long-term benefits in adults with obesity

Setmelanotide delivers long-term benefits in adults with obesity

CTC-DMARD lowers risk of treatment failure in nonanterior sarcoidosis uveitis

CTC-DMARD lowers risk of treatment failure in nonanterior sarcoidosis uveitis

Ketamine infusions no better than midazolam infusions for inpatient depression treatment

Ketamine infusions no better than midazolam infusions for inpatient depression treatment

Original New Drug Application Approvals by US FDA (16-30 September 2025)

Original New Drug Application Approvals by US FDA (16-30 September 2025)

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-September-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-September-2025

Cagrilintide-semaglutide tied to weight loss in adults with obesity, T2D

Cagrilintide-semaglutide tied to weight loss in adults with obesity, T2D

Reducing pharmaceutical sodium content helps manage BP elevations in narcolepsy

Reducing pharmaceutical sodium content helps manage BP elevations in narcolepsy